Resource Type

Journal Article 1

Year

2016 1

Keywords

AZD9291 1

EAI045 1

EGFR 1

tyrosine kinase inhibitor 1

Search scope:

排序: Display mode:

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors

Shuhang Wang,Yongping Song,Feifei Yan,Delong Liu

Frontiers of Medicine 2016, Volume 10, Issue 4,   Pages 383-388 doi: 10.1007/s11684-016-0488-1

Abstract: AZD9291 (osimertinib; Tagrisso) is the first and only FDA approved third-generation EGFR TKI for T790M-positiveHowever, resistance to AZD9291 arises after 9–13 months of therapy.To overcome the acquired resistance to AZD9291, EAI045 was discovered and recently reported to be an

Keywords: EGFR     tyrosine kinase inhibitor     AZD9291     EAI045    

Title Author Date Type Operation

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors

Shuhang Wang,Yongping Song,Feifei Yan,Delong Liu

Journal Article